Elizabeth Kovacs
Concepts (575)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Burns | 65 | 2026 | 377 | 18.510 |
Why?
| | Ethanol | 57 | 2026 | 627 | 9.180 |
Why?
| | Alcoholic Intoxication | 16 | 2025 | 74 | 6.170 |
Why?
| | Alcohol Drinking | 26 | 2025 | 826 | 4.680 |
Why?
| | Pneumonia | 14 | 2025 | 631 | 4.470 |
Why?
| | Aging | 28 | 2025 | 1966 | 3.770 |
Why?
| | Inflammation | 33 | 2025 | 2880 | 3.620 |
Why?
| | Gastrointestinal Microbiome | 11 | 2026 | 771 | 3.430 |
Why?
| | Alcoholism | 23 | 2025 | 817 | 2.960 |
Why?
| | Lung Transplantation | 15 | 2019 | 338 | 2.450 |
Why?
| | Immunity, Innate | 12 | 2017 | 846 | 2.390 |
Why?
| | Cytokines | 20 | 2025 | 2065 | 2.200 |
Why?
| | Interleukin-6 | 16 | 2025 | 780 | 2.170 |
Why?
| | Mice | 72 | 2026 | 18365 | 2.050 |
Why?
| | Liver Diseases | 6 | 2025 | 304 | 2.050 |
Why?
| | Mice, Inbred C57BL | 41 | 2026 | 5997 | 2.040 |
Why?
| | Macrophages, Alveolar | 9 | 2022 | 368 | 2.010 |
Why?
| | Lung | 25 | 2025 | 4109 | 2.000 |
Why?
| | Feces | 4 | 2025 | 513 | 1.990 |
Why?
| | Neutrophils | 16 | 2022 | 1134 | 1.940 |
Why?
| | Animals | 102 | 2026 | 38109 | 1.900 |
Why?
| | Dysbiosis | 5 | 2025 | 187 | 1.870 |
Why?
| | Burns, Inhalation | 5 | 2020 | 9 | 1.830 |
Why?
| | Intestines | 4 | 2022 | 358 | 1.810 |
Why?
| | Binge Drinking | 8 | 2023 | 44 | 1.750 |
Why?
| | Wound Healing | 11 | 2015 | 351 | 1.700 |
Why?
| | Macrophages | 13 | 2016 | 1511 | 1.630 |
Why?
| | Gastroesophageal Reflux | 10 | 2014 | 236 | 1.610 |
Why?
| | Glycerophospholipids | 6 | 2025 | 39 | 1.610 |
Why?
| | Bacterial Translocation | 8 | 2026 | 52 | 1.600 |
Why?
| | Bronchoalveolar Lavage Fluid | 15 | 2018 | 636 | 1.550 |
Why?
| | Age Factors | 17 | 2025 | 3335 | 1.450 |
Why?
| | Lung Diseases | 9 | 2018 | 787 | 1.440 |
Why?
| | Disease Models, Animal | 25 | 2025 | 4569 | 1.420 |
Why?
| | Intestinal Mucosa | 5 | 2025 | 676 | 1.320 |
Why?
| | Phagocytosis | 7 | 2016 | 299 | 1.310 |
Why?
| | Smoke Inhalation Injury | 6 | 2013 | 30 | 1.260 |
Why?
| | Neutrophil Infiltration | 8 | 2016 | 104 | 1.230 |
Why?
| | Biomarkers | 21 | 2025 | 4275 | 1.150 |
Why?
| | Respiratory Aspiration | 4 | 2013 | 32 | 1.150 |
Why?
| | Liver | 12 | 2025 | 1888 | 1.130 |
Why?
| | Public Opinion | 4 | 2023 | 62 | 1.130 |
Why?
| | Pancreatitis-Associated Proteins | 2 | 2025 | 12 | 1.120 |
Why?
| | Pseudomonas Infections | 4 | 2016 | 221 | 1.070 |
Why?
| | Male | 86 | 2026 | 72406 | 1.050 |
Why?
| | Central Nervous System Depressants | 3 | 2015 | 83 | 1.040 |
Why?
| | Macrophage Activation | 6 | 2019 | 193 | 1.040 |
Why?
| | Antimicrobial Cationic Peptides | 2 | 2025 | 86 | 1.020 |
Why?
| | Immune System | 5 | 2017 | 179 | 0.960 |
Why?
| | Bronchiolitis Obliterans | 6 | 2014 | 66 | 0.940 |
Why?
| | Colon | 2 | 2025 | 305 | 0.930 |
Why?
| | Calgranulin A | 1 | 2025 | 11 | 0.920 |
Why?
| | Postoperative Complications | 8 | 2025 | 2920 | 0.920 |
Why?
| | Radiation Injuries, Experimental | 3 | 2013 | 20 | 0.890 |
Why?
| | Blood-Brain Barrier | 1 | 2026 | 155 | 0.870 |
Why?
| | Fatty Acid-Binding Proteins | 1 | 2025 | 79 | 0.860 |
Why?
| | tau Proteins | 1 | 2025 | 115 | 0.850 |
Why?
| | Wound Infection | 2 | 2016 | 57 | 0.830 |
Why?
| | Pneumonia, Bacterial | 2 | 2016 | 113 | 0.830 |
Why?
| | Mice, Inbred BALB C | 12 | 2020 | 1253 | 0.780 |
Why?
| | Humans | 103 | 2025 | 144957 | 0.780 |
Why?
| | Cellular Senescence | 1 | 2025 | 226 | 0.780 |
Why?
| | Central Nervous System | 1 | 2025 | 281 | 0.780 |
Why?
| | Skin | 6 | 2016 | 758 | 0.770 |
Why?
| | Chemokines | 8 | 2023 | 218 | 0.750 |
Why?
| | Radiation Injuries | 2 | 2016 | 151 | 0.730 |
Why?
| | Biomedical Research | 4 | 2018 | 710 | 0.710 |
Why?
| | Pneumonia, Pneumococcal | 1 | 2022 | 47 | 0.700 |
Why?
| | Delirium | 1 | 2023 | 104 | 0.690 |
Why?
| | Tight Junctions | 1 | 2021 | 81 | 0.680 |
Why?
| | Signal Transduction | 14 | 2022 | 5233 | 0.670 |
Why?
| | Pneumococcal Infections | 1 | 2022 | 103 | 0.670 |
Why?
| | Female | 64 | 2025 | 78376 | 0.670 |
Why?
| | Immunity, Cellular | 5 | 2018 | 272 | 0.670 |
Why?
| | Astrocytes | 1 | 2022 | 224 | 0.640 |
Why?
| | Pore Forming Cytotoxic Proteins | 1 | 2020 | 15 | 0.620 |
Why?
| | Leukocytes | 3 | 2011 | 295 | 0.620 |
Why?
| | Estrogens | 2 | 2016 | 380 | 0.610 |
Why?
| | Wounds and Injuries | 4 | 2015 | 957 | 0.610 |
Why?
| | Allergy and Immunology | 2 | 2017 | 42 | 0.600 |
Why?
| | von Willebrand Factor | 1 | 2019 | 85 | 0.590 |
Why?
| | Hepatitis, Alcoholic | 1 | 2018 | 16 | 0.560 |
Why?
| | Gastrointestinal Tract | 2 | 2020 | 208 | 0.560 |
Why?
| | Tumor Necrosis Factor-alpha | 6 | 2022 | 1217 | 0.560 |
Why?
| | Fatty Liver | 3 | 2017 | 251 | 0.560 |
Why?
| | Pseudomonas aeruginosa | 5 | 2014 | 356 | 0.560 |
Why?
| | Immunosenescence | 2 | 2017 | 5 | 0.560 |
Why?
| | Pepsin A | 3 | 2014 | 18 | 0.550 |
Why?
| | Epigenesis, Genetic | 4 | 2022 | 685 | 0.550 |
Why?
| | Flow Cytometry | 6 | 2018 | 1173 | 0.550 |
Why?
| | Cell Proliferation | 1 | 2025 | 2499 | 0.540 |
Why?
| | Mesenchymal Stem Cell Transplantation | 1 | 2018 | 59 | 0.540 |
Why?
| | Immunity | 3 | 2025 | 139 | 0.540 |
Why?
| | Aged | 25 | 2025 | 25947 | 0.520 |
Why?
| | Chemokine CCL2 | 1 | 2017 | 116 | 0.520 |
Why?
| | Sepsis | 5 | 2023 | 641 | 0.500 |
Why?
| | Histone Deacetylase 1 | 1 | 2016 | 23 | 0.490 |
Why?
| | Chemokine CXCL1 | 3 | 2025 | 76 | 0.490 |
Why?
| | Middle Aged | 31 | 2025 | 35928 | 0.490 |
Why?
| | Kupffer Cells | 1 | 2016 | 53 | 0.490 |
Why?
| | Spleen | 5 | 2011 | 508 | 0.480 |
Why?
| | Myosin-Light-Chain Kinase | 2 | 2014 | 19 | 0.480 |
Why?
| | Pulmonary Edema | 1 | 2016 | 106 | 0.480 |
Why?
| | Tissue Donors | 3 | 2018 | 424 | 0.480 |
Why?
| | Prenatal Exposure Delayed Effects | 1 | 2023 | 675 | 0.470 |
Why?
| | Inflammation Mediators | 6 | 2015 | 509 | 0.470 |
Why?
| | Length of Stay | 3 | 2019 | 1337 | 0.470 |
Why?
| | Granulocyte Colony-Stimulating Factor | 2 | 2013 | 89 | 0.460 |
Why?
| | Laparoscopy | 5 | 2014 | 475 | 0.460 |
Why?
| | Adaptive Immunity | 2 | 2016 | 169 | 0.460 |
Why?
| | p38 Mitogen-Activated Protein Kinases | 1 | 2016 | 266 | 0.450 |
Why?
| | Intestine, Small | 2 | 2016 | 166 | 0.450 |
Why?
| | Microbiota | 1 | 2023 | 781 | 0.450 |
Why?
| | Bradykinin B2 Receptor Antagonists | 1 | 2015 | 1 | 0.440 |
Why?
| | Adult | 33 | 2025 | 40506 | 0.440 |
Why?
| | Bradykinin | 1 | 2015 | 48 | 0.440 |
Why?
| | Models, Animal | 6 | 2019 | 392 | 0.440 |
Why?
| | Oxidative Stress | 6 | 2025 | 1339 | 0.430 |
Why?
| | Immunologic Memory | 1 | 2017 | 366 | 0.430 |
Why?
| | Respiration | 1 | 2015 | 207 | 0.430 |
Why?
| | Extracellular Traps | 1 | 2015 | 57 | 0.430 |
Why?
| | Dehydration | 1 | 2015 | 56 | 0.430 |
Why?
| | Primary Graft Dysfunction | 1 | 2014 | 35 | 0.420 |
Why?
| | Esophageal pH Monitoring | 1 | 2014 | 22 | 0.420 |
Why?
| | Lipopolysaccharides | 5 | 2012 | 863 | 0.410 |
Why?
| | Breath Tests | 3 | 2016 | 79 | 0.410 |
Why?
| | Histones | 2 | 2016 | 670 | 0.400 |
Why?
| | Alanine Transaminase | 5 | 2025 | 151 | 0.400 |
Why?
| | Monocytes | 1 | 2016 | 538 | 0.400 |
Why?
| | Apoptosis | 7 | 2025 | 2430 | 0.390 |
Why?
| | Congresses as Topic | 4 | 2020 | 221 | 0.390 |
Why?
| | Scleroderma, Systemic | 1 | 2014 | 123 | 0.380 |
Why?
| | Ileitis | 1 | 2013 | 33 | 0.380 |
Why?
| | Dendritic Cells | 3 | 2016 | 499 | 0.380 |
Why?
| | Solvents | 1 | 2013 | 113 | 0.380 |
Why?
| | Chemotaxis, Leukocyte | 1 | 2013 | 113 | 0.370 |
Why?
| | Graft Rejection | 2 | 2013 | 540 | 0.370 |
Why?
| | Permeability | 3 | 2022 | 168 | 0.370 |
Why?
| | Research Personnel | 1 | 2014 | 186 | 0.370 |
Why?
| | Career Choice | 1 | 2014 | 237 | 0.370 |
Why?
| | Leukocyte Count | 5 | 2013 | 316 | 0.370 |
Why?
| | Mentors | 1 | 2014 | 219 | 0.360 |
Why?
| | Intestinal Diseases | 1 | 2012 | 43 | 0.360 |
Why?
| | Staphylococcal Infections | 2 | 2013 | 390 | 0.360 |
Why?
| | rac GTP-Binding Proteins | 1 | 2012 | 34 | 0.360 |
Why?
| | Phagosomes | 1 | 2012 | 40 | 0.360 |
Why?
| | Fundoplication | 1 | 2012 | 54 | 0.360 |
Why?
| | Injury Severity Score | 5 | 2017 | 600 | 0.350 |
Why?
| | Receptors, IgG | 1 | 2012 | 76 | 0.350 |
Why?
| | Antibodies | 2 | 2013 | 403 | 0.350 |
Why?
| | Ischemia | 1 | 2015 | 421 | 0.340 |
Why?
| | Toll-Like Receptor 4 | 2 | 2010 | 276 | 0.340 |
Why?
| | Risk Factors | 12 | 2025 | 10792 | 0.340 |
Why?
| | Immunologic Factors | 2 | 2016 | 255 | 0.330 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 9 | 2018 | 851 | 0.330 |
Why?
| | Ligands | 2 | 2023 | 674 | 0.330 |
Why?
| | Logistic Models | 6 | 2019 | 2119 | 0.330 |
Why?
| | Prospective Studies | 9 | 2021 | 7997 | 0.330 |
Why?
| | Aspartate Aminotransferases | 3 | 2025 | 85 | 0.320 |
Why?
| | Down-Regulation | 1 | 2013 | 627 | 0.320 |
Why?
| | Cell Separation | 1 | 2011 | 307 | 0.320 |
Why?
| | Mice, Knockout | 7 | 2013 | 3125 | 0.320 |
Why?
| | Cause of Death | 3 | 2019 | 472 | 0.310 |
Why?
| | Intercellular Adhesion Molecule-1 | 1 | 2010 | 138 | 0.310 |
Why?
| | Respiratory Function Tests | 3 | 2025 | 547 | 0.310 |
Why?
| | Actins | 1 | 2012 | 425 | 0.300 |
Why?
| | Protein Precursors | 2 | 2025 | 137 | 0.300 |
Why?
| | Toll-Like Receptor 2 | 1 | 2010 | 126 | 0.300 |
Why?
| | Immune Tolerance | 1 | 2012 | 379 | 0.300 |
Why?
| | Ileum | 2 | 2024 | 111 | 0.300 |
Why?
| | Environmental Pollutants | 1 | 2011 | 167 | 0.300 |
Why?
| | Receptors, Interleukin-8B | 2 | 2010 | 23 | 0.290 |
Why?
| | Interleukin-12 | 2 | 2013 | 117 | 0.290 |
Why?
| | Illinois | 4 | 2017 | 47 | 0.280 |
Why?
| | Occludin | 2 | 2021 | 11 | 0.280 |
Why?
| | Smoking | 2 | 2013 | 1472 | 0.270 |
Why?
| | Cathelicidins | 2 | 2025 | 41 | 0.270 |
Why?
| | Time Factors | 9 | 2019 | 7183 | 0.270 |
Why?
| | Gastroenteritis | 1 | 2008 | 63 | 0.260 |
Why?
| | Plethysmography | 2 | 2019 | 109 | 0.260 |
Why?
| | Bronchoscopy | 3 | 2013 | 227 | 0.260 |
Why?
| | Peroxidase | 3 | 2016 | 168 | 0.250 |
Why?
| | Respiration, Artificial | 1 | 2012 | 708 | 0.250 |
Why?
| | Young Adult | 9 | 2025 | 14126 | 0.250 |
Why?
| | Microglia | 2 | 2026 | 269 | 0.250 |
Why?
| | Peptides | 1 | 2012 | 998 | 0.240 |
Why?
| | Statistics, Nonparametric | 5 | 2013 | 427 | 0.240 |
Why?
| | Trachea | 1 | 2008 | 261 | 0.230 |
Why?
| | Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2025 | 73 | 0.230 |
Why?
| | Cholera Toxin | 1 | 2025 | 29 | 0.230 |
Why?
| | Laparotomy | 1 | 2025 | 112 | 0.220 |
Why?
| | Ubiquitin Thiolesterase | 1 | 2025 | 68 | 0.220 |
Why?
| | Skin Ulcer | 2 | 2015 | 14 | 0.220 |
Why?
| | Glial Fibrillary Acidic Protein | 1 | 2025 | 125 | 0.220 |
Why?
| | Neurofilament Proteins | 1 | 2025 | 80 | 0.220 |
Why?
| | Bacteria | 3 | 2023 | 889 | 0.220 |
Why?
| | Bacteroidetes | 1 | 2024 | 21 | 0.220 |
Why?
| | Haptoglobins | 1 | 2025 | 66 | 0.220 |
Why?
| | Mitochondria, Liver | 1 | 2025 | 70 | 0.210 |
Why?
| | Fecal Microbiota Transplantation | 1 | 2024 | 26 | 0.210 |
Why?
| | Exhalation | 2 | 2016 | 29 | 0.210 |
Why?
| | Retrospective Studies | 10 | 2023 | 17101 | 0.210 |
Why?
| | Survival Analysis | 3 | 2019 | 1385 | 0.210 |
Why?
| | Burn Units | 2 | 2022 | 48 | 0.200 |
Why?
| | ROC Curve | 5 | 2018 | 615 | 0.200 |
Why?
| | Toxoplasmosis | 1 | 2024 | 43 | 0.200 |
Why?
| | Toxoplasma | 1 | 2024 | 49 | 0.200 |
Why?
| | NLR Family, Pyrin Domain-Containing 3 Protein | 1 | 2025 | 169 | 0.200 |
Why?
| | Fatty Acids, Volatile | 1 | 2024 | 60 | 0.200 |
Why?
| | Multivariate Analysis | 3 | 2023 | 1540 | 0.200 |
Why?
| | Hepatocytes | 1 | 2025 | 224 | 0.200 |
Why?
| | Hospital Mortality | 2 | 2019 | 1031 | 0.200 |
Why?
| | Receptors, G-Protein-Coupled | 1 | 2025 | 233 | 0.200 |
Why?
| | Aged, 80 and over | 5 | 2017 | 8279 | 0.200 |
Why?
| | Homeostasis | 2 | 2020 | 640 | 0.200 |
Why?
| | Cohort Studies | 9 | 2019 | 5965 | 0.200 |
Why?
| | Hawaii | 1 | 2023 | 46 | 0.190 |
Why?
| | Zonula Occludens-1 Protein | 2 | 2013 | 16 | 0.190 |
Why?
| | alpha-Defensins | 1 | 2022 | 11 | 0.190 |
Why?
| | Whole-Body Irradiation | 2 | 2013 | 76 | 0.190 |
Why?
| | Phenotype | 4 | 2020 | 3164 | 0.190 |
Why?
| | Body Surface Area | 1 | 2022 | 35 | 0.190 |
Why?
| | Mitochondrial Proteins | 1 | 2025 | 263 | 0.190 |
Why?
| | Caspases | 1 | 2023 | 232 | 0.180 |
Why?
| | Veterans Health | 1 | 2024 | 189 | 0.180 |
Why?
| | Sex Characteristics | 3 | 2016 | 791 | 0.180 |
Why?
| | Fluorescent Antibody Technique | 3 | 2014 | 370 | 0.180 |
Why?
| | Interleukin-1beta | 3 | 2020 | 395 | 0.170 |
Why?
| | Veterans | 2 | 2024 | 1603 | 0.170 |
Why?
| | Neurodegenerative Diseases | 1 | 2023 | 151 | 0.170 |
Why?
| | Critical Illness | 2 | 2018 | 892 | 0.170 |
Why?
| | Malondialdehyde | 1 | 2021 | 30 | 0.170 |
Why?
| | NF-kappa B | 1 | 2025 | 662 | 0.170 |
Why?
| | Interleukins | 2 | 2014 | 248 | 0.170 |
Why?
| | Injections, Intraperitoneal | 2 | 2013 | 117 | 0.170 |
Why?
| | Phosphorylation | 3 | 2016 | 1733 | 0.170 |
Why?
| | Analysis of Variance | 3 | 2014 | 1311 | 0.160 |
Why?
| | Lipid Peroxidation | 1 | 2021 | 160 | 0.160 |
Why?
| | Frailty | 1 | 2024 | 198 | 0.160 |
Why?
| | Hippocampus | 2 | 2025 | 967 | 0.160 |
Why?
| | Ventricular Dysfunction, Right | 1 | 2023 | 248 | 0.160 |
Why?
| | Streptococcus pneumoniae | 1 | 2022 | 177 | 0.160 |
Why?
| | Caspase 3 | 3 | 2023 | 238 | 0.160 |
Why?
| | Boston | 1 | 2020 | 92 | 0.160 |
Why?
| | Resistin | 1 | 2019 | 12 | 0.150 |
Why?
| | Organ Specificity | 1 | 2020 | 313 | 0.150 |
Why?
| | Gastric Inhibitory Polypeptide | 1 | 2019 | 13 | 0.150 |
Why?
| | Ghrelin | 1 | 2019 | 39 | 0.150 |
Why?
| | Metformin | 1 | 2023 | 319 | 0.150 |
Why?
| | Cells, Cultured | 7 | 2016 | 4155 | 0.150 |
Why?
| | Mannose-Binding Lectins | 1 | 2019 | 10 | 0.150 |
Why?
| | Plasminogen Activator Inhibitor 1 | 1 | 2019 | 84 | 0.150 |
Why?
| | Natural Killer T-Cells | 2 | 2010 | 67 | 0.150 |
Why?
| | Lectins, C-Type | 1 | 2019 | 62 | 0.150 |
Why?
| | Fires | 1 | 2020 | 87 | 0.150 |
Why?
| | Glutathione | 1 | 2021 | 375 | 0.150 |
Why?
| | Predictive Value of Tests | 3 | 2019 | 2118 | 0.150 |
Why?
| | Air Pollutants | 1 | 2024 | 438 | 0.150 |
Why?
| | Life Style | 2 | 2014 | 479 | 0.150 |
Why?
| | Risk Assessment | 5 | 2019 | 3676 | 0.140 |
Why?
| | Cell Count | 2 | 2016 | 321 | 0.140 |
Why?
| | Multiple Organ Failure | 2 | 2017 | 124 | 0.140 |
Why?
| | Nanoparticles | 1 | 2025 | 520 | 0.140 |
Why?
| | Proteasome Endopeptidase Complex | 2 | 2010 | 159 | 0.140 |
Why?
| | In Situ Nick-End Labeling | 1 | 2018 | 121 | 0.140 |
Why?
| | Administration, Oral | 2 | 2013 | 848 | 0.140 |
Why?
| | Glucagon-Like Peptide 1 | 1 | 2019 | 146 | 0.140 |
Why?
| | Leptin | 1 | 2019 | 245 | 0.140 |
Why?
| | Prognosis | 3 | 2018 | 4293 | 0.130 |
Why?
| | Linear Models | 2 | 2017 | 854 | 0.130 |
Why?
| | Cognitive Dysfunction | 1 | 2023 | 464 | 0.130 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 1 | 2020 | 983 | 0.130 |
Why?
| | Toll-Like Receptors | 2 | 2009 | 194 | 0.130 |
Why?
| | RNA, Ribosomal, 16S | 1 | 2020 | 559 | 0.130 |
Why?
| | Mental Health | 1 | 2024 | 792 | 0.130 |
Why?
| | Receptors, Cell Surface | 1 | 2019 | 377 | 0.130 |
Why?
| | Tobacco Use | 1 | 2017 | 61 | 0.120 |
Why?
| | Reproducibility of Results | 2 | 2019 | 3415 | 0.120 |
Why?
| | Needs Assessment | 1 | 2019 | 404 | 0.120 |
Why?
| | Diet | 2 | 2014 | 1275 | 0.120 |
Why?
| | Transcriptome | 1 | 2023 | 1046 | 0.120 |
Why?
| | Intensive Care Units | 4 | 2019 | 916 | 0.120 |
Why?
| | Follow-Up Studies | 2 | 2018 | 5417 | 0.120 |
Why?
| | United States | 10 | 2024 | 15988 | 0.120 |
Why?
| | Monocyte Chemoattractant Proteins | 1 | 2015 | 7 | 0.120 |
Why?
| | Ovariectomy | 1 | 2016 | 162 | 0.120 |
Why?
| | Chemokine CXCL2 | 1 | 2015 | 41 | 0.120 |
Why?
| | Incidence | 3 | 2019 | 2883 | 0.120 |
Why?
| | Dose-Response Relationship, Drug | 3 | 2010 | 2032 | 0.120 |
Why?
| | Acetylation | 1 | 2016 | 256 | 0.120 |
Why?
| | Regression Analysis | 3 | 2013 | 1003 | 0.110 |
Why?
| | Apicomplexa | 1 | 2015 | 3 | 0.110 |
Why?
| | Polymerase Chain Reaction | 1 | 2018 | 1054 | 0.110 |
Why?
| | Phylogeny | 1 | 2020 | 1019 | 0.110 |
Why?
| | Imidazoles | 1 | 2016 | 254 | 0.110 |
Why?
| | Brain | 2 | 2026 | 2941 | 0.110 |
Why?
| | Negative-Pressure Wound Therapy | 1 | 2015 | 28 | 0.110 |
Why?
| | Enzyme Inhibitors | 2 | 2016 | 826 | 0.110 |
Why?
| | Hematocrit | 1 | 2015 | 108 | 0.110 |
Why?
| | Wasting Syndrome | 1 | 2014 | 12 | 0.110 |
Why?
| | Killer Cells, Natural | 2 | 2008 | 469 | 0.110 |
Why?
| | Gene Expression | 2 | 2018 | 1490 | 0.110 |
Why?
| | Electric Stimulation Therapy | 1 | 2015 | 63 | 0.110 |
Why?
| | Radiation Dosage | 1 | 2016 | 193 | 0.110 |
Why?
| | Fast Foods | 1 | 2014 | 17 | 0.110 |
Why?
| | Alcohol-Related Disorders | 1 | 2015 | 120 | 0.100 |
Why?
| | Respiratory Tract Diseases | 1 | 2016 | 175 | 0.100 |
Why?
| | Cognition | 1 | 2023 | 1269 | 0.100 |
Why?
| | Systemic Inflammatory Response Syndrome | 2 | 2014 | 96 | 0.100 |
Why?
| | Interleukin-23 | 1 | 2014 | 16 | 0.100 |
Why?
| | Chi-Square Distribution | 2 | 2013 | 529 | 0.100 |
Why?
| | Insulin | 2 | 2019 | 2507 | 0.100 |
Why?
| | Leukocyte Disorders | 1 | 2014 | 9 | 0.100 |
Why?
| | Health | 1 | 2014 | 81 | 0.100 |
Why?
| | Caspase 8 | 1 | 2013 | 47 | 0.100 |
Why?
| | Sex Factors | 4 | 2019 | 2114 | 0.100 |
Why?
| | Receptors, Aryl Hydrocarbon | 1 | 2014 | 60 | 0.100 |
Why?
| | Immune System Diseases | 1 | 2014 | 39 | 0.100 |
Why?
| | Fungi | 1 | 2015 | 161 | 0.100 |
Why?
| | Lymphocyte Subsets | 1 | 2013 | 83 | 0.100 |
Why?
| | Faculty | 1 | 2014 | 149 | 0.100 |
Why?
| | Lung Injury | 1 | 2016 | 237 | 0.100 |
Why?
| | Myosin Light Chains | 1 | 2013 | 28 | 0.100 |
Why?
| | Th17 Cells | 1 | 2014 | 101 | 0.100 |
Why?
| | Creatinine | 1 | 2015 | 506 | 0.090 |
Why?
| | Viruses | 1 | 2015 | 165 | 0.090 |
Why?
| | Immunoassay | 1 | 2013 | 109 | 0.090 |
Why?
| | Employment | 1 | 2014 | 188 | 0.090 |
Why?
| | Bile Acids and Salts | 1 | 2014 | 164 | 0.090 |
Why?
| | Adipose Tissue | 2 | 2015 | 653 | 0.090 |
Why?
| | Calcitonin | 1 | 2012 | 27 | 0.090 |
Why?
| | Bacterial Load | 1 | 2012 | 67 | 0.090 |
Why?
| | Vinculin | 1 | 2012 | 10 | 0.090 |
Why?
| | Paxillin | 1 | 2012 | 11 | 0.090 |
Why?
| | Syndrome | 1 | 2013 | 380 | 0.090 |
Why?
| | Anti-Infective Agents | 1 | 2015 | 242 | 0.090 |
Why?
| | Pyridines | 1 | 2016 | 605 | 0.090 |
Why?
| | Social Class | 1 | 2014 | 268 | 0.090 |
Why?
| | Receptors, Interleukin-4 | 1 | 2011 | 16 | 0.090 |
Why?
| | Interleukin 1 Receptor Antagonist Protein | 1 | 2013 | 254 | 0.090 |
Why?
| | Decidua | 1 | 1992 | 22 | 0.090 |
Why?
| | Receptors, Interleukin-2 | 1 | 1992 | 64 | 0.090 |
Why?
| | Chorionic Villi | 1 | 1992 | 25 | 0.090 |
Why?
| | Focal Adhesions | 1 | 2012 | 47 | 0.090 |
Why?
| | Cell Differentiation | 2 | 2016 | 2050 | 0.090 |
Why?
| | Hypertension, Pulmonary | 1 | 2023 | 1980 | 0.090 |
Why?
| | rho GTP-Binding Proteins | 1 | 2012 | 56 | 0.090 |
Why?
| | Research Support as Topic | 1 | 2012 | 80 | 0.090 |
Why?
| | Ubiquitin | 1 | 2012 | 86 | 0.090 |
Why?
| | Chemokine CXCL12 | 1 | 2012 | 89 | 0.090 |
Why?
| | Pregnancy | 2 | 2023 | 7191 | 0.090 |
Why?
| | Nitric Oxide Synthase Type II | 1 | 2011 | 162 | 0.090 |
Why?
| | Polymerization | 1 | 2012 | 130 | 0.080 |
Why?
| | Gene Expression Regulation, Enzymologic | 1 | 2012 | 269 | 0.080 |
Why?
| | Vehicle Emissions | 1 | 2011 | 62 | 0.080 |
Why?
| | Confidence Intervals | 1 | 2012 | 333 | 0.080 |
Why?
| | Phagocytes | 2 | 2009 | 81 | 0.080 |
Why?
| | Pulmonary Alveoli | 1 | 2013 | 383 | 0.080 |
Why?
| | Nitric Oxide | 1 | 2016 | 897 | 0.080 |
Why?
| | Blood Glucose | 2 | 2019 | 2330 | 0.080 |
Why?
| | Immunohistochemistry | 1 | 2015 | 1718 | 0.080 |
Why?
| | Cytoskeleton | 1 | 2012 | 195 | 0.080 |
Why?
| | Edema | 1 | 2011 | 124 | 0.080 |
Why?
| | Tissue Engineering | 1 | 2015 | 442 | 0.080 |
Why?
| | Writing | 1 | 2012 | 100 | 0.080 |
Why?
| | Bone Marrow Cells | 1 | 2011 | 320 | 0.080 |
Why?
| | Body Composition | 1 | 2014 | 706 | 0.080 |
Why?
| | Specimen Handling | 1 | 2012 | 186 | 0.080 |
Why?
| | Dermatitis | 1 | 2010 | 19 | 0.080 |
Why?
| | Equipment Design | 1 | 2012 | 530 | 0.080 |
Why?
| | Ozone | 1 | 2011 | 132 | 0.080 |
Why?
| | Bacteremia | 1 | 2012 | 221 | 0.080 |
Why?
| | DNA | 2 | 2015 | 1464 | 0.080 |
Why?
| | Heart Failure | 1 | 2023 | 2323 | 0.080 |
Why?
| | Adiposity | 1 | 2014 | 543 | 0.080 |
Why?
| | Respiration Disorders | 1 | 2010 | 78 | 0.070 |
Why?
| | Endoscopy, Gastrointestinal | 1 | 2011 | 237 | 0.070 |
Why?
| | Trophoblasts | 1 | 1992 | 216 | 0.070 |
Why?
| | Adolescent | 5 | 2017 | 22453 | 0.070 |
Why?
| | Interleukin-18 | 1 | 2010 | 235 | 0.070 |
Why?
| | Cystic Fibrosis | 1 | 2019 | 1158 | 0.070 |
Why?
| | Odds Ratio | 1 | 2012 | 1077 | 0.070 |
Why?
| | Severity of Illness Index | 2 | 2019 | 2925 | 0.070 |
Why?
| | Histiocytes | 1 | 2008 | 7 | 0.070 |
Why?
| | Mass Screening | 2 | 2015 | 1348 | 0.070 |
Why?
| | Escherichia coli K12 | 1 | 2008 | 8 | 0.070 |
Why?
| | Membrane Fluidity | 1 | 2008 | 8 | 0.070 |
Why?
| | Acute Lung Injury | 1 | 2012 | 303 | 0.070 |
Why?
| | bcl-X Protein | 2 | 2023 | 45 | 0.070 |
Why?
| | Kaplan-Meier Estimate | 1 | 2011 | 966 | 0.070 |
Why?
| | Interleukin-2 | 1 | 2009 | 437 | 0.070 |
Why?
| | Hypersensitivity, Delayed | 1 | 2008 | 29 | 0.070 |
Why?
| | Membrane Microdomains | 1 | 2008 | 34 | 0.070 |
Why?
| | Receptors, Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2008 | 16 | 0.070 |
Why?
| | Feeding Behavior | 1 | 2014 | 685 | 0.070 |
Why?
| | Vascular Endothelial Growth Factor Receptor-2 | 1 | 2008 | 85 | 0.070 |
Why?
| | Opportunistic Infections | 1 | 2008 | 45 | 0.070 |
Why?
| | Protein Kinase Inhibitors | 1 | 2014 | 970 | 0.070 |
Why?
| | Manometry | 3 | 2013 | 97 | 0.070 |
Why?
| | Shock | 1 | 2009 | 108 | 0.070 |
Why?
| | Comorbidity | 3 | 2019 | 1660 | 0.070 |
Why?
| | Asthma | 2 | 2016 | 1768 | 0.070 |
Why?
| | Cell Survival | 2 | 2025 | 1098 | 0.070 |
Why?
| | Capillary Permeability | 1 | 2008 | 134 | 0.070 |
Why?
| | Testis | 1 | 2008 | 163 | 0.070 |
Why?
| | Protein Kinases | 1 | 2009 | 315 | 0.060 |
Why?
| | Intubation, Gastrointestinal | 1 | 2008 | 82 | 0.060 |
Why?
| | Staphylococcus aureus | 1 | 2011 | 460 | 0.060 |
Why?
| | Pediatric Obesity | 1 | 2014 | 638 | 0.060 |
Why?
| | Survival Rate | 1 | 2012 | 2092 | 0.060 |
Why?
| | Mast Cells | 1 | 2008 | 146 | 0.060 |
Why?
| | Neovascularization, Physiologic | 1 | 2008 | 194 | 0.060 |
Why?
| | Hydrogen-Ion Concentration | 3 | 2013 | 561 | 0.060 |
Why?
| | In Vitro Techniques | 1 | 2008 | 1048 | 0.060 |
Why?
| | Hypothalamo-Hypophyseal System | 1 | 2008 | 198 | 0.060 |
Why?
| | Reproduction | 1 | 2008 | 207 | 0.060 |
Why?
| | Gonadal Steroid Hormones | 1 | 2008 | 144 | 0.060 |
Why?
| | Angiogenesis Inhibitors | 1 | 2008 | 237 | 0.060 |
Why?
| | Interleukin-1 | 1 | 2010 | 961 | 0.060 |
Why?
| | Cell Line | 1 | 2012 | 2882 | 0.060 |
Why?
| | Interferon-gamma | 1 | 2009 | 784 | 0.060 |
Why?
| | Keratin-18 | 1 | 2025 | 12 | 0.060 |
Why?
| | Cell Communication | 1 | 2008 | 324 | 0.060 |
Why?
| | Idiopathic Pulmonary Fibrosis | 1 | 2013 | 691 | 0.060 |
Why?
| | Eosinophils | 1 | 2008 | 316 | 0.060 |
Why?
| | Research Design | 1 | 2012 | 1137 | 0.060 |
Why?
| | Reference Values | 2 | 2019 | 798 | 0.060 |
Why?
| | Treatment Outcome | 2 | 2012 | 11695 | 0.060 |
Why?
| | Sensitivity and Specificity | 3 | 2018 | 1990 | 0.060 |
Why?
| | Serum Amyloid A Protein | 1 | 2025 | 32 | 0.060 |
Why?
| | Kynurenine | 1 | 2025 | 114 | 0.060 |
Why?
| | Polymorphism, Genetic | 1 | 2008 | 612 | 0.050 |
Why?
| | Acute Disease | 1 | 2008 | 1031 | 0.050 |
Why?
| | Barrett Esophagus | 3 | 2012 | 165 | 0.050 |
Why?
| | Tryptophan | 1 | 2025 | 181 | 0.050 |
Why?
| | Lomustine | 1 | 2024 | 15 | 0.050 |
Why?
| | Anti-Inflammatory Agents | 1 | 2008 | 475 | 0.050 |
Why?
| | Antioxidants | 1 | 2008 | 549 | 0.050 |
Why?
| | Antibodies, Protozoan | 1 | 2024 | 41 | 0.050 |
Why?
| | Neoplasms | 2 | 2016 | 2884 | 0.050 |
Why?
| | Gene Silencing | 1 | 2025 | 205 | 0.050 |
Why?
| | Hemorrhage | 1 | 2009 | 809 | 0.050 |
Why?
| | Metals, Heavy | 1 | 2024 | 32 | 0.050 |
Why?
| | Inflammasomes | 1 | 2025 | 146 | 0.050 |
Why?
| | Anti-Bacterial Agents | 1 | 2014 | 1915 | 0.050 |
Why?
| | Pesticides | 1 | 2024 | 63 | 0.050 |
Why?
| | Caspase 9 | 1 | 2023 | 55 | 0.050 |
Why?
| | Case-Control Studies | 4 | 2015 | 3608 | 0.050 |
Why?
| | Europe | 2 | 2014 | 412 | 0.050 |
Why?
| | STAT3 Transcription Factor | 1 | 2025 | 207 | 0.050 |
Why?
| | Prednisone | 1 | 2024 | 221 | 0.050 |
Why?
| | Surveys and Questionnaires | 4 | 2019 | 6053 | 0.050 |
Why?
| | Immunoglobulin M | 1 | 2024 | 284 | 0.050 |
Why?
| | Exercise | 1 | 2014 | 2201 | 0.050 |
Why?
| | Lymphocytes | 1 | 1984 | 382 | 0.040 |
Why?
| | Virulence | 1 | 2023 | 280 | 0.040 |
Why?
| | Endothelial Cells | 1 | 2008 | 870 | 0.040 |
Why?
| | AMP-Activated Protein Kinases | 1 | 2023 | 191 | 0.040 |
Why?
| | Reactive Oxygen Species | 1 | 2025 | 621 | 0.040 |
Why?
| | DNA Repair | 1 | 1984 | 256 | 0.040 |
Why?
| | Energy Metabolism | 1 | 2008 | 936 | 0.040 |
Why?
| | Liver Cirrhosis | 1 | 2023 | 288 | 0.040 |
Why?
| | Hernia, Hiatal | 2 | 2012 | 41 | 0.040 |
Why?
| | Blood Alcohol Content | 1 | 2021 | 6 | 0.040 |
Why?
| | Colorado | 2 | 2024 | 4564 | 0.040 |
Why?
| | Ventricular Remodeling | 1 | 2023 | 276 | 0.040 |
Why?
| | Ventricular Function, Right | 1 | 2023 | 297 | 0.040 |
Why?
| | Air Pollution | 1 | 2024 | 327 | 0.040 |
Why?
| | Immunoglobulin G | 1 | 2024 | 893 | 0.040 |
Why?
| | Firefighters | 1 | 2020 | 47 | 0.040 |
Why?
| | Environmental Exposure | 1 | 2024 | 590 | 0.040 |
Why?
| | MicroRNAs | 1 | 2025 | 701 | 0.040 |
Why?
| | United States Department of Veterans Affairs | 1 | 2024 | 768 | 0.040 |
Why?
| | Chronic Disease | 2 | 2015 | 1813 | 0.040 |
Why?
| | Patient-Centered Care | 1 | 2024 | 544 | 0.040 |
Why?
| | Patient Care Team | 1 | 2024 | 689 | 0.030 |
Why?
| | Vascular Endothelial Growth Factor A | 2 | 2013 | 557 | 0.030 |
Why?
| | Half-Life | 1 | 2018 | 151 | 0.030 |
Why?
| | Reference Standards | 1 | 2018 | 178 | 0.030 |
Why?
| | Age of Onset | 1 | 2019 | 551 | 0.030 |
Why?
| | California | 1 | 2019 | 475 | 0.030 |
Why?
| | National Heart, Lung, and Blood Institute (U.S.) | 1 | 2017 | 103 | 0.030 |
Why?
| | Disease Progression | 2 | 2015 | 2852 | 0.030 |
Why?
| | Shock, Septic | 1 | 2019 | 216 | 0.030 |
Why?
| | Forkhead Box Protein O3 | 1 | 2016 | 18 | 0.030 |
Why?
| | International Classification of Diseases | 1 | 2017 | 147 | 0.030 |
Why?
| | Dried Blood Spot Testing | 1 | 2017 | 126 | 0.030 |
Why?
| | Gene Expression Profiling | 1 | 2023 | 1786 | 0.030 |
Why?
| | Academic Medical Centers | 1 | 2019 | 548 | 0.030 |
Why?
| | Bronchoalveolar Lavage | 1 | 2015 | 89 | 0.030 |
Why?
| | Propensity Score | 1 | 2017 | 367 | 0.030 |
Why?
| | Rats | 3 | 2014 | 5614 | 0.030 |
Why?
| | Histocompatibility Antigens Class II | 1 | 2016 | 364 | 0.030 |
Why?
| | Endocrine System | 1 | 2014 | 22 | 0.030 |
Why?
| | Administration, Topical | 1 | 2015 | 150 | 0.030 |
Why?
| | Self Report | 1 | 2019 | 873 | 0.030 |
Why?
| | Psoriasis | 1 | 2015 | 112 | 0.030 |
Why?
| | Anthropometry | 1 | 2014 | 200 | 0.030 |
Why?
| | Hemostasis | 1 | 2014 | 102 | 0.030 |
Why?
| | Prevalence | 2 | 2011 | 2836 | 0.020 |
Why?
| | Pneumonia, Aspiration | 1 | 2013 | 16 | 0.020 |
Why?
| | Principal Component Analysis | 1 | 2014 | 198 | 0.020 |
Why?
| | C-Reactive Protein | 1 | 2016 | 417 | 0.020 |
Why?
| | Canada | 1 | 2015 | 428 | 0.020 |
Why?
| | Culture | 1 | 2014 | 125 | 0.020 |
Why?
| | Chemokine CCL5 | 1 | 2013 | 41 | 0.020 |
Why?
| | Virus Diseases | 1 | 2015 | 216 | 0.020 |
Why?
| | Area Under Curve | 1 | 2014 | 331 | 0.020 |
Why?
| | Forecasting | 1 | 2015 | 391 | 0.020 |
Why?
| | Critical Care | 1 | 2019 | 697 | 0.020 |
Why?
| | Acute-Phase Proteins | 1 | 2012 | 67 | 0.020 |
Why?
| | Gene Expression Regulation | 2 | 2013 | 2609 | 0.020 |
Why?
| | Disease Management | 1 | 2016 | 647 | 0.020 |
Why?
| | Health Surveys | 1 | 2014 | 518 | 0.020 |
Why?
| | Calcitonin Gene-Related Peptide | 1 | 2012 | 40 | 0.020 |
Why?
| | Diagnosis, Differential | 1 | 2016 | 1495 | 0.020 |
Why?
| | Technetium Tc 99m Sulfur Colloid | 1 | 2012 | 6 | 0.020 |
Why?
| | Barium Sulfate | 1 | 2012 | 13 | 0.020 |
Why?
| | Cross-Sectional Studies | 1 | 2024 | 5872 | 0.020 |
Why?
| | Societies, Medical | 1 | 2016 | 887 | 0.020 |
Why?
| | Fluorescence | 1 | 2012 | 161 | 0.020 |
Why?
| | Gastric Emptying | 1 | 2012 | 36 | 0.020 |
Why?
| | Metabolomics | 1 | 2017 | 727 | 0.020 |
Why?
| | Pregnancy Trimester, First | 1 | 1992 | 136 | 0.020 |
Why?
| | T-Lymphocytes, Helper-Inducer | 1 | 1992 | 131 | 0.020 |
Why?
| | Monitoring, Ambulatory | 1 | 2012 | 89 | 0.020 |
Why?
| | Radiopharmaceuticals | 1 | 2012 | 207 | 0.020 |
Why?
| | Esophagitis | 1 | 2011 | 66 | 0.020 |
Why?
| | DNA Fragmentation | 1 | 2010 | 39 | 0.020 |
Why?
| | Liver Transplantation | 1 | 2018 | 823 | 0.020 |
Why?
| | bcl-2-Associated X Protein | 1 | 2010 | 54 | 0.020 |
Why?
| | Drug Administration Routes | 1 | 2010 | 44 | 0.020 |
Why?
| | Pneumonia, Viral | 1 | 2015 | 384 | 0.020 |
Why?
| | Morbidity | 1 | 2011 | 323 | 0.020 |
Why?
| | Membrane Glycoproteins | 1 | 2012 | 496 | 0.020 |
Why?
| | Chromatography, Gel | 1 | 2009 | 131 | 0.020 |
Why?
| | Antigens, CD1d | 1 | 2009 | 68 | 0.020 |
Why?
| | Abortion, Induced | 1 | 1992 | 110 | 0.020 |
Why?
| | Radiography | 1 | 2012 | 845 | 0.020 |
Why?
| | Esophagus | 1 | 2011 | 261 | 0.020 |
Why?
| | Child, Preschool | 2 | 2014 | 11799 | 0.020 |
Why?
| | Pulmonary Disease, Chronic Obstructive | 1 | 2016 | 923 | 0.020 |
Why?
| | T-Lymphocytes, Regulatory | 1 | 1992 | 389 | 0.020 |
Why?
| | Reoperation | 1 | 2012 | 631 | 0.020 |
Why?
| | Nursing Assessment | 1 | 2009 | 56 | 0.020 |
Why?
| | Contrast Media | 1 | 2012 | 488 | 0.020 |
Why?
| | Cell Movement | 1 | 2013 | 965 | 0.020 |
Why?
| | tert-Butyl Alcohol | 1 | 2008 | 1 | 0.020 |
Why?
| | Transforming Growth Factor beta1 | 1 | 2009 | 178 | 0.020 |
Why?
| | Alcohol Dehydrogenase | 1 | 2008 | 16 | 0.020 |
Why?
| | Drug Administration Schedule | 1 | 2010 | 783 | 0.020 |
Why?
| | Carrier Proteins | 1 | 2012 | 737 | 0.020 |
Why?
| | Transforming Growth Factor beta | 1 | 1991 | 479 | 0.020 |
Why?
| | Oligopeptides | 1 | 2010 | 269 | 0.020 |
Why?
| | Antibodies, Neutralizing | 1 | 2010 | 341 | 0.020 |
Why?
| | Cell Hypoxia | 1 | 2008 | 247 | 0.020 |
Why?
| | Collagen | 1 | 2009 | 456 | 0.020 |
Why?
| | Lymphocyte Activation | 1 | 2010 | 1126 | 0.010 |
Why?
| | Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2008 | 298 | 0.010 |
Why?
| | Risk-Taking | 1 | 2009 | 328 | 0.010 |
Why?
| | Body Mass Index | 1 | 2014 | 2438 | 0.010 |
Why?
| | Fibroblasts | 1 | 1991 | 1034 | 0.010 |
Why?
| | Cell Nucleus | 1 | 2008 | 619 | 0.010 |
Why?
| | Rats, Sprague-Dawley | 1 | 2010 | 2540 | 0.010 |
Why?
| | T-Lymphocytes | 1 | 2013 | 1982 | 0.010 |
Why?
| | Hydroxyurea | 1 | 1984 | 34 | 0.010 |
Why?
| | Child | 2 | 2014 | 22657 | 0.010 |
Why?
| | Pyrazoles | 1 | 2008 | 510 | 0.010 |
Why?
| | Testosterone | 1 | 2008 | 419 | 0.010 |
Why?
| | Quality of Life | 1 | 2015 | 3192 | 0.010 |
Why?
| | Ultraviolet Rays | 1 | 1984 | 388 | 0.010 |
Why?
| | Registries | 1 | 2008 | 2385 | 0.010 |
Why?
| | Bleomycin | 1 | 1991 | 253 | 0.000 |
Why?
| | Oxygen | 1 | 1991 | 995 | 0.000 |
Why?
| | RNA, Messenger | 1 | 1991 | 2832 | 0.000 |
Why?
|
|
Kovacs's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|